TLSA Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 16:00):

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology...

Stats
Today's Volume	881 804
Average Volume	155 704
Market Cap	84.61M
EPS	$0 ( 2024-04-24 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-5.61
ATR14	$0.00300 (0.36%)

Volume Correlation

Long: -0.08 (neutral)

Short: -0.43 (neutral)

Signal:(39.928) Neutral

Tiziana Life Sciences PLC Correlation

10 Most Positive Correlations
AMTX	0.848
ENNV	0.845
MDVL	0.845
KVSB	0.843
CLNE	0.842
MOVE	0.839
DVAX	0.827
EQ	0.824
GPOR	0.823
HCDIP	0.822

10 Most Negative Correlations
BNIXU	-0.867
PAYA	-0.85
HBANO	-0.832
MGNI	-0.832
USLM	-0.831
LSTR	-0.827
ISIG	-0.821
TIPT	-0.82
RNLC	-0.82
STAY	-0.816

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Tiziana Life Sciences PLC Correlation - Currency/Commodity

0.56
( weak )

0.67
( moderate )

0.00
( neutral )

0.42
( neutral )

Tiziana Life Sciences PLC Financials

Annual	2022
Revenue:	$0
Gross Profit:	$-51 000.00 (0.00 %)
EPS:	$-0.160

Q2	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$0

Q4	2022
Revenue:	$0
Gross Profit:	$-46 000.00 (0.00 %)
EPS:	$-0.110

Q2	2020
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.0202

Financial Reports:

No articles found.

Tiziana Life Sciences PLC

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. The company was incorporated in 1998 and is headquatered in London, the United Kingdom.